LivaNova Beheer

Mr. Vladimir A. Makatsaria has been the Chief Executive Officer and Director at LivaNova PLC since March 01, 2024. He is a Non-Executive Director of the Health Products Regulatory Authority Board in Irelan...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alex Shvartsburg	Chief Financial Officer	4yrs	US$2.77m	0.034% $ 979.9k
Michael Hutchinson	Senior VP	2yrs	US$2.07m	0.0042% $ 119.6k
Vladimir Makatsaria	CEO & Director	less than a year	geen gegevens	geen gegevens
Lindsey Little	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Deanna Wilke	Vice President of Corporate Communications	no data	geen gegevens	geen gegevens
Matthew Dodds	Senior Vice President of Corporate Development & IT	6.8yrs	geen gegevens	geen gegevens
Paul Buckman	President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	no data	geen gegevens	geen gegevens
Stephanie Bolton	President of Global Epilepsy	4.8yrs	geen gegevens	0.018% $ 500.3k
Ahmet Tezel	Chief Innovation Officer	less than a year	geen gegevens	geen gegevens
Franco Poletti	President of Cardiopulmonary Business Unit	less than a year	geen gegevens	0.013% $ 360.2k
John Webb	Vice President of Sleep Apnea and Epilepsy	no data	geen gegevens	geen gegevens
Jonathan Walker	VP for Difficult-to-Treat Depression Segment	no data	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LIVN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vladimir Makatsaria	CEO & Director	less than a year	geen gegevens	geen gegevens
Todd Schermerhorn	Independent Non-Executive Director	3.9yrs	US$270.00k	0.011% $ 316.8k
Peter Wilver	Independent Director	2.4yrs	US$263.00k	0.0069% $ 195.2k
William Kozy	Chairman of Board	6.4yrs	US$3.34m	0.051% $ 1.4m
Sharon O'Kane	Independent Non-Executive Director	9.1yrs	US$281.43k	0.017% $ 496.6k
Stacy Seng	Independent Non-Executive Director	5.4yrs	US$260.00k	0.016% $ 457.4k
Francesco Bianchi	Independent Non-Executive Director	9.1yrs	US$263.00k	0.016% $ 458.8k
Susan Podlogar	Independent Director	less than a year	geen gegevens	geen gegevens
J. Barry	Independent Director	1.1yrs	US$117.88k	geen gegevens
Brooke Story	Independent Director	2.2yrs	US$248.00k	0.0064% $ 181.8k

3.2yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LIVN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

LivaNova Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

LivaNova PLC Appoints Susan Podlogar as New Director

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Independent Director notifies of intention to sell stock

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Recent updates

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova PLC Appoints Susan Podlogar as New Director

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?

LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger

At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

Independent Director notifies of intention to sell stock

LivaNova: Focus Is Paying Off

Now 21% undervalued

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

Now 21% overvalued after recent price rise

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% overvalued after recent price rise

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry

LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

New minor risk - Earnings quality

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

LivaNova PLC Announces Board Changes

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Price target increased by 7.7% to US$65.33

LivaNova PLC Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.1% to US$62.25

Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital

CEO & Director exercised options and sold US$432k worth of stock

What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?

CEO & Director exercised options and sold US$805k worth of stock

Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021)

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)